未知股票 AFMD 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 1639.23万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 1.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Delisting of Securities from The Nasdaq Stock Market
The Nasdaq Stock Market announced on July 11, 2025, that it will delist the securities of multiple companies, including NKGen Biotech, Inc., Aquaron Acquisition Corp., Bannix Acquisition Corp., Avenue Therapeutics, Inc., WinVest Acquisition Corp., IMAC Holdings, Inc., Lytus Technologies Holdings PTV Ltd., Luokung Technology Corp., Aptose Biosciences, Inc., Virpax Pharmaceuticals, Inc., Phoenix Motor Inc., Denali Capital Acquisition Corp., Thunder...
2025-07-11 20:05
3 Penny Stocks to Watch Now, 5/20/25
Virgin Galactic Holdings, Affimed N.V., and Amesite Inc. are the 3Penny S...
2025-05-20 17:14
美股大行评级 | On Holding获多家机构上调"买入"评级！美银证券首予亿航智能"买入"评级，目标价26美元
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
2025-05-15 08:45
HC Wainwright & Co. Downgrades Affimed to Neutral
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Affimed (NASDAQ:AFMD) from Buy to Neutral.
2025-05-15 01:03
Affimed Receives Nasdaq Delisting Notice; Trading To Be Suspended May 20
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the
2025-05-14 18:47
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
2025-05-14 08:48
Affimed Files for Insolvency Amid Financial Challenges
The latest update is out from Affimed ( ($AFMD) ). On May 13, 2025, Affimed N.V...
2025-05-13 20:48
Leerink Partners Downgrades Affimed to Market Perform, Lowers Price Target to $0.39
Leerink Partners analyst Daina Graybosch downgrades Affimed (NASDAQ:AFMD) from Outperform to Market Perform and lowers the price target from $5 to $0.39.
2025-05-13 18:54
Affimed receives Nasdaq non-compliance notice
Affimed (NASDAQ:AFMD) has received a notice from The Nasdaq Stock Market LLC for its failure to comply with the exchange’s minimum $1.00 per share continued listing requirement. For the last 30 consec...
2025-04-21 18:47
Affimed’s Potential in Cancer Treatment: Navigating Challenges with Strategic Partnerships
Affimed (AFMD – Research Report), the Healthcare sector company, was revisited ...
2024-12-21 01:59
